EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Developmental Toxicity Study for the Antimalarial Drug Combination Cabamiquine‐Pyronaridine Using a Translational Approach

Wookyung Kim, Geum-Sil Cho, Andreas Gado, Tobias Hyun Ho Baeurle iD, Habib Karimi, Filippo Venezia, Claude Oeuvray, Thomas Spangenberg iD, Sebastian G Wicha, Claudia Demarta-Gatsi iD

Birth Defects Research · 2026

DOI: 10.1002/bdr2.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Birth Defects Research, 2026. Verfasst von Wookyung Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Headquarters, Shin Poong Pharm. Co., Ltd., Ansan, Republic of Korea. Hauptthemen laut MEDLINE: Antimalarials, Naphthyridines. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The healthcare business of Merck KGaA, Darmstadt, Germany, The Right Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety of pharmacological treatments during pregnancy is a significant concern, as many medications lack comprehensive reproductive safety data. This creates gaps in therapeutic options for pregnant women, particularly malaria, which poses serious risks to maternal and fetal health. Additionally, there is an urgent need to develop combination therapies for which reproductive safety data are currently unavailable, further complicating treatment options for this vulnerable population. The combination of cabamiquine and pyronaridine emerges as a promising solution; however, since no reproductive safety data exist for this combination, comprehensive evaluations are essential to ensure maternal and fetal well‐being. Materials and Methods The cabamiquine–pyronaridine combination was evaluated using an in vivo embryo‐fetal development (EFD) toxicity study in rats and a Zebrafish Embryo Developmental Toxicity Assay (ZEDTA), following regulatory frameworks. Zebrafish developmental toxicity data were further integrated using pharmacokinetic and toxicokinetic modeling to assess safety margins and predict potential toxicity at anticipated clinical study doses and exposures.

Results

Combined administration of cabamiquine and pyronaridine showed no significant impact on prenatal outcomes. Both compounds exhibited dose‐proportional increases in maternal systemic exposure, with no fetal mortality or adverse findings. No adverse effects on embryo‐fetal development were observed at the previously defined monotherapy NOAEL doses, indicating the absence of adverse drug–drug interactions. Safety assessments at higher doses in the ZEDTA revealed no toxicity effects at ongoing clinical study doses. Pharmacokinetics and toxicokinetics modeling do not suggest the potential of cabamiquine and pyronaridine to cause toxicity at the forecast clinical study doses and anticipated exposures.

Discussion

The combined findings from the rat EFD study, ZEDTA, and model‐based pharmacokinetic and toxicokinetic analyses consistently demonstrated the absence of developmental toxicity and adverse drug‐drug interactions across multiple complementary approaches. These data provide confidence that the combination is unlikely to pose developmental safety concerns at clinically relevant exposures.

Conclusion

These findings support the clinical development of the cabamiquine–pyronaridine combination for women of childbearing potential and provide a foundation for future clinical evaluation during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsNaphthyridinesAnimalsFemaleZebrafishRatsPregnancyEmbryonic DevelopmentToxicity TestsMalariaFetal DevelopmentRats, Sprague-Dawley

Stichwörter der Autor:innen

Cabamiquine‐Pyronaridine combinationEFD ratPK/TK modelingZEDTApregnancy‐associated malaria

Substanzen

pyronaridineAntimalarialsNaphthyridines

Autor:innen und Institutionen

  • Research Headquarters, Shin Poong Pharm. Co., Ltd., Ansan, Republic of Korea.
  • The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Global Health R&D of the Healthcare Business of Merck KGaA, Darmstadt, Germany, Ares Trading S.A. (An Affiliate of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland.
  • Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.

ORCID-Profile: Tobias Hyun Ho Baeurle, Thomas Spangenberg, Claudia Demarta-Gatsi

Förderung

  • The healthcare business of Merck KGaA, Darmstadt, Germany
  • The Right Foundation

Zitieren

APA

Kim, W., Cho, G. S., Gado, A., Baeurle, T. H. H., Karimi, H., Venezia, F., Oeuvray, C., Spangenberg, T., Wicha, S. G., & Demarta-Gatsi, C. (2026). Developmental Toxicity Study for the Antimalarial Drug Combination Cabamiquine‐Pyronaridine Using a Translational Approach. Birth Defects Research. https://doi.org/10.1002/bdr2.70105

Vancouver

Kim W, Cho GS, Gado A, Baeurle THH, Karimi H, Venezia F, et al. Developmental Toxicity Study for the Antimalarial Drug Combination Cabamiquine‐Pyronaridine Using a Translational Approach. Birth Defects Research. 2026. doi:10.1002/bdr2.70105

BibTeX
@article{Kim2026,
  author = {Kim, Wookyung and Cho, Geum-Sil and Gado, Andreas and Baeurle, Tobias Hyun Ho and Karimi, Habib and Venezia, Filippo and Oeuvray, Claude and Spangenberg, Thomas and Wicha, Sebastian G and Demarta-Gatsi, Claudia},
  title = {Developmental Toxicity Study for the Antimalarial Drug Combination Cabamiquine‐Pyronaridine Using a Translational Approach},
  journal = {Birth Defects Research},
  year = {2026},
  doi = {10.1002/bdr2.70105}
}
Kostenlos starten →